ARTHEx Biotech S.L. (private company)

See something wrong or missing? Let us know
Offices:
Valencia
Business model:
B2B
Investors:
we tracked 1 investor
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 1 transaction

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases.

Companies with similar profile to ARTHEx Biotech S.L.:

CompanyCriteria
Sweden Scandinavian Real Hearts
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Finland Sooma Medical
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Spain Vytrus Biotech
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Spain ViveBiotech
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Denmark Cirqle Biomedical
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Spain Algenex
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Sigrid Therapeutics
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Denmark CysBio
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden Gedea Biotech
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Denmark STipe Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark AFYX Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Norway SonoClear
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Iceland Alvotech
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark NMD Pharma
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Finland Tenboron
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Finland DelSiTech
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Norway APIM Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Denmark InProTher
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Spain Sanifit Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Finland Optomed
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes